Helen Hobbs - Pfizer Independent Director
PFE Stock | EUR 24.50 0.09 0.37% |
Director
Dr. Helen H. Hobbs, M.D., is an Independent Director of Pfizer Inc., since December 12, 2011. She is Investigator, the Howard Hughes Medical Institute since 2002, Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the National Academy of Sciences in 2007. Received both the Clinical Research Prize and Distinguished Scientist Award from the American Heart Association. In 2012, received the inaugural International Society of Atherosclerosis Prize and in 2015, received both the Pearl Meister Greengard Award and the Breakthrough Prize in Life Sciences. In 2016, received the Passano Award and the Gill Award since 2011.
Age | 65 |
Tenure | 13 years |
Phone | 212 733 2323 |
Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1287 % which means that it generated a profit of $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3622 %, meaning that it generated $0.3622 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Michael Eskew | Eli Lilly and | 66 | |
Erik Fyrwald | Eli Lilly and | 56 | |
Edward Liddy | AbbVie Inc | 72 | |
Roy Roberts | AbbVie Inc | 69 | |
Glenn Tilton | AbbVie Inc | 69 | |
Brett Hart | AbbVie Inc | 48 | |
William Kaelin | Eli Lilly and | 58 | |
Jamere Jackson | Eli Lilly and | 47 | |
Franklyn Prendergast | Eli Lilly and | 70 | |
Juan Luciano | Eli Lilly and | 54 | |
Frederick Waddell | AbbVie Inc | 64 | |
Jackson Tai | Eli Lilly and | 66 | |
Katherine Baicker | Eli Lilly and | 44 | |
Marschall Runge | Eli Lilly and | 61 | |
Robert Alpern | AbbVie Inc | 67 | |
Rebecca Roberts | AbbVie Inc | 65 | |
Ralph Alvarez | Eli Lilly and | 61 | |
Karen Horn | Eli Lilly and | 71 | |
David Hoover | Eli Lilly and | 71 | |
Carolyn Bertozzi | Eli Lilly and | 49 | |
Raul Alvarez | Eli Lilly and | 61 |
Management Performance
Return On Equity | 0.36 | |||
Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President - Global Established Pharma Business | ||
Jennifer Damico, Controller VP | ||
Frank DAmelio, CFO, Executive Vice President - Business Operations | ||
Douglas Lankler, Executive Vice President General Counsel | ||
Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
Helen Hobbs, Independent Director | ||
Shantanu Narayen, Director | ||
James Smith, Director | ||
Christopher CFA, VP Officer | ||
Dennis Ausiello, Independent Director | ||
Mikael Dolsten, President - Worldwide Research and Development | ||
Frances Fergusson, Independent Director | ||
Stephen Sanger, Independent Director | ||
Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
Wyllie Cornwell, Independent Director | ||
Suzanne Johnson, Independent Director | ||
David Denton, Chief VP | ||
Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
DVM DVM, Chairman CEO | ||
Geno Germano, Group President - Global Innovative Pharma Business | ||
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
Sally Susman, Executive Vice President - Corporate Affairs | ||
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
Freda LewisHall, Executive Vice President Chief Medical Officer | ||
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer | ||
Mikael MD, Dev Research | ||
Dan Littman, Director | ||
Ian Read, Chairman of the Board, CEO | ||
James Kilts, Independent Director | ||
Don Cornwell, Independent Director | ||
Charles Hill, Executive Vice President - Worldwide Human Resources | ||
Joseph Echevarria, Director | ||
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
Angela Hwang, Group President - Pfizer Essential Health | ||
Scott Gottlieb, Director | ||
Ronald Blaylock, Independent Director | ||
Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.36 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.31 % | |||
Operating Margin | 0.39 % | |||
Current Valuation | 276.06 B | |||
Shares Outstanding | 5.62 B | |||
Shares Owned By Insiders | 0.04 % | |||
Shares Owned By Institutions | 71.00 % | |||
Price To Earning | 16.17 X | |||
Price To Book | 3.13 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |